Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer?

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.16
Views: 2710

Prof Charles Ryan and Prof Nick James

Prof Nick James (Warwick medical School Cancer Research, University of Warwick, UK) and Prof Charles Ryan (UCSF School of Medicine, San Francisco, USA) had an expert discussion summarising the practice changing data from ASCO 2016 regarding chemotherapy treatment.

They discuss what is the optimal chemotherapy dosing regimen and whether intermittent versus continuous chemotherapy treatment has an impact on overall survival and quality of life.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation